We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Walgreens' Weak Market Trends a Woe, Strategic Deals to Aid
Read MoreHide Full Article
On Apr 9, we issued an updated research report on Walgreens Boots Alliance, Inc. (WBA - Free Report) . The company faces headwinds in the form of fierce competition and tough industry conditions. However, at the same time, it consistently reaps benefits from its growth initiatives and major business tie-ups. The stock carries a Zacks Rank #4 (Sell).
Walgreens Boots reported dismal second-quarter fiscal 2019 results, mainly due to disturbance in the U.S. and UK consumer markets, lower generic deflation, soft brand inflation and higher reimbursement pressure. The company anticipates these pharmacy trends, which are impacting the overall market, to persist over the coming months.
Accordingly, it has lowered its fiscal 2019 adjusted EPS growth expectations. Over the past month, shares of the company have underperformed its industry. The stock has declined 10.2%, wider than the industry’s 1.3% fall.
On a positive note, in the reported quarter, the Retail Pharmacy USA division saw comparable prescription growth and benefited from a strong retail prescription market. Within this segment, Walgreens Boots has been making a good progress owing to its expanding prescription volumes.
The company is currently making concerted efforts to fix specific areas of operational weakness and is bolstering its managerial efficiency to improve operational excellence with a deepened focus.
The company has been gaining traction from strategic tie-ups as well. We are looking forward to Walgreens Boots’ recent alliance with Alphabet’s life sciences and healthcare segment — Verily — to coordinate on multiple projects related to chronic ailments. Also, the company’s collaborations with Express Scripts and Kroger are aimed to expand its existing group purchasing efforts and product offerings, respectively.
Stryker’s long-term earnings growth rate is projected at 10%
Penumbra’s long-term earnings growth rate is estimated at 20.9%.
Amedisys’s long-term earnings growth rate is forecast at 19.7%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Walgreens' Weak Market Trends a Woe, Strategic Deals to Aid
On Apr 9, we issued an updated research report on Walgreens Boots Alliance, Inc. (WBA - Free Report) . The company faces headwinds in the form of fierce competition and tough industry conditions. However, at the same time, it consistently reaps benefits from its growth initiatives and major business tie-ups. The stock carries a Zacks Rank #4 (Sell).
Walgreens Boots reported dismal second-quarter fiscal 2019 results, mainly due to disturbance in the U.S. and UK consumer markets, lower generic deflation, soft brand inflation and higher reimbursement pressure. The company anticipates these pharmacy trends, which are impacting the overall market, to persist over the coming months.
Accordingly, it has lowered its fiscal 2019 adjusted EPS growth expectations. Over the past month, shares of the company have underperformed its industry. The stock has declined 10.2%, wider than the industry’s 1.3% fall.
On a positive note, in the reported quarter, the Retail Pharmacy USA division saw comparable prescription growth and benefited from a strong retail prescription market. Within this segment, Walgreens Boots has been making a good progress owing to its expanding prescription volumes.
The company is currently making concerted efforts to fix specific areas of operational weakness and is bolstering its managerial efficiency to improve operational excellence with a deepened focus.
The company has been gaining traction from strategic tie-ups as well. We are looking forward to Walgreens Boots’ recent alliance with Alphabet’s life sciences and healthcare segment — Verily — to coordinate on multiple projects related to chronic ailments. Also, the company’s collaborations with Express Scripts and Kroger are aimed to expand its existing group purchasing efforts and product offerings, respectively.
Key Picks
Some better-ranked stocks in the broader medical space are Stryker Corporation (SYK - Free Report) , Penumbra, Inc. (PEN - Free Report) and Amedisys, Inc (AMED - Free Report) , each stock currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker’s long-term earnings growth rate is projected at 10%
Penumbra’s long-term earnings growth rate is estimated at 20.9%.
Amedisys’s long-term earnings growth rate is forecast at 19.7%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>